Abstract
AbstractThe aim of the present study was to use an in vitro–in silico approach to predict the in vivo acute liver toxicity of monocrotaline and to characterize the influence of its metabolism on its relative toxic potency compared to lasiocarpine and riddelliine. In the absence of data on acute liver toxicity of monocrotaline upon oral exposure, the predicted dose–response curve for acute liver toxicity in rats and the resulting benchmark dose lower and upper confidence limits for 10% effect (BMDL10 and BMDU10) were compared to data obtained in studies with intraperitoneal or subcutaneous dosing regimens. This indicated the predicted BMDL10 value to be in line with the no-observed-adverse-effect levels (NOAELs) derived from availabe in vivo studies. The predicted BMDL10–BMDU10 of 1.1–4.9 mg/kg bw/day also matched the oral dose range of 1–3 mg PA/kg bw/day at which adverse effects in human are reported. A comparison to the oral toxicity of the related pyrrolizidine alkaloids (PAs) lasiocarpine and riddelliine revealed that, although in the rat hepatocytes monocrotaline was less toxic than lasiocarpine and riddelliine, due to its relatively inefficient clearance, its in vivo acute liver toxicity was predicted to be comparable. It is concluded that the combined in vitro-PBK modeling approach can provide insight in monocrotaline-induced acute liver toxicity in rats, thereby filling existing gaps in the database on PA toxicity. Furthermore, the results reveal that the kinetic and metabolic properties of PAs can vary substantially and should be taken into account when considering differences in relative potency between different PAs.
Funder
Indonesian Endowment Fund for Education, Ministry of Finance, Republic of Indonesia through a Beasiswa Pendidikan Indonesia Lembaga Pengelola Dana Pendidikan (BPI LPDP) doctoral scholarship
Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Toxicology,General Medicine
Reference61 articles.
1. Adams R, Rogers EF (1939) The structure of monocrotaline, the alkaloid in Crotalaria spectabilis and Crotalaria retusa I. J Am Chem Soc 61(10):2815–2819. https://doi.org/10.1021/ja01265a073
2. Agents Classified by the IARC Monographs, Volumes 1–125 (2019) International Agency for Research on Cancer. https://monographs.iarc.fr/agents-classified-by-the-iarc/. Accessed 6 December 2019
3. Barnes DG, Dourson M, Dourson M et al (1988) Reference dose (RfD): Description and use in health risk assessments. Regul Toxicol Pharmacol 8(4):471–486. https://doi.org/10.1016/0273-2300(88)90047-5
4. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR et al (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407–484. https://doi.org/10.1177/074823379701300401
5. Bull LB, Culvenor Ct, Dick A (1968) The pyrrolizidine alkaloids: their chemistry, pathogenicity and other biological properties. QRB 45(1):67. https://doi.org/10.1086/406383
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献